Biogen is handing over a staggering $350 million in cash for a partnership with Sangamo Therapeutics. The deal will leverage gene therapy to develop Alzheimer’s and Parkinson’s drugs.

Related Posts

• 

  Drug company Pfizer announced overnight that its COVID-19 vaccine may be 90 per cent effective in stopping the virus — but it’s not at the finish line yet. Here are five things you need to know about this announcement.

  10/11/2020

• 

  Nikola’s new leadership may be bringing discipline to its product roadmap.

  10/11/2020

• 

  Executive powers and federal agency will enable the incoming U.S. president to reverse the slashing of environmental regulations of the past four years

  09/11/2020